Ser296

Site Information
ETNKRFssLsyKsRE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4717867

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:	breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 2 , 4 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , Calu 6 (pulmonary) ( 4 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 5 ) , Flp-In T-Rex-293 (epithelial) ( 5 ) , H2077 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , Jurkat (T lymphocyte) ( 3 , 6 , 7 , 8 , 9 , 10 , 11 ) , lung ( 2 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H157 (pulmonary) ( 4 ) , NCI-H1648 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 )

References
1	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
2	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
6	Mulhern D (2011) CST Curation Set: 12684; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
7	Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
8	Mulhern D (2011) CST Curation Set: 12678; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
9	Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
10	Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
11	Zhou J (2009) CST Curation Set: 6053; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info